Lactic Acid Bacteria for Reducing Blue Light-Induced Eye Fatigue | NCT07737938

NCT07737938

Overview

NCT ID: NCT07737938
Lead Sponsor: Synbio Tech Inc.INDUSTRY
Official Title: The Application of Lactic Acid Bacteria on Reducing Blue Light-Induced Eye Fatigue in Middle-Aged Adults
Brief Summary: With the widespread use of digital devices and prolonged screen exposure, digital eye strain (DES), also known as computer vision syndrome, has become a global public health concern. Emerging evidence suggests that the gut-eye axis may play an important role in ocular health, as gut microbiota imbalance is associated with systemic inflammation and oxidative stress. Specific probiotics may help alleviate eye discomfort through modulation of immune responses and enhancement of antioxidant defense mechanisms. This randomized, double-blind, placebo-controlled study aims to evaluate the efficacy of supplementation with specific probiotics, Bifidobacterium longum BL531 and Lactobacillus reuteri LR1349, in improving digital eye strain symptoms in adults.
Conditions: Digital Eye Strain (DES)

Status and Timeline

Status: Not yet recruiting
Last Update Posted: Jul 30, 2026Actual
Start Date: Sep 1, 2026Estimated
Primary Completion Date: Aug 31, 2027Estimated
Completion Date

Participation Criteria

Ages Eligible for Study: Adult (18-64)Older Adult (65+)
Sexes Eligible for Study: All
Accepts Healthy Volunteers?: Yes
Eligibility Criteria: Inclusion Criteria:

Men and women aged 20-65 years

Daily digital screen use >6 hours for at least 1 year

Mild to severe digital eye strain (CVS-Q score ≥ 6)

Mild to moderate dry eye symptoms (OSDI ≥ 13)

Exclusion Criteria:

Amblyopia or strabismus

Severe eye diseases (e.g., glaucoma , cataract , retinal disorders, severe corneal disease)

Ocular surgery within the past 12 months

Chronic systemic diseases (e.g., uncontrolled diabetes, autoimmune disease, severe liver/kidney impairment, cancer)

Recent use (<1 months) of steroids, antibiotics, immunosuppressants, probiotics, prebiotics, or eye-health supplements

Pregnant or breastfeeding

Allergy to probiotics or study product ingredients

Eating disorders, psychiatric illness, or cognitive impairment affecting compliance

Any condition judged unsuitable by the investigator

Study Plan

Study Type: Interventional
Phase: Not Applicable
Enrollment: 150Estimated
Primary Purpose: Prevention
Allocation: Randomized
Interventional Model: Parallel Assignment
Masking: Double

Contacts and Locations

Central Contacts: Han-Yin HsuContact
hanin@synbiotech.com.tw+886-07-6955680 Ext. 2923

Similar Studies

Participant Group/Arms

PlaceboPlacebo Comparator

Subjects assigned to the placebo group will take one placebo capsule daily within 30 minutes before breakfast throughout the 12-week intervention period.

Dietary Supplement: Placebo

BL531_low doseExperimental

Subjects assigned to each intervention group will take one capsule daily within 30 minutes before breakfast throughout the 12-week intervention period.

Dietary Supplement: BL531_low dose

BL531_high doseExperimental

Subjects assigned to each intervention group will take one capsule daily within 30 minutes before breakfast throughout the 12-week intervention period.

Dietary Supplement: BL531_high dose

LR1349_low doseExperimental

Subjects assigned to each intervention group will take one capsule daily within 30 minutes before breakfast throughout the 12-week intervention period.

Dietary Supplement: LR1349_low dose

LR1349_high doseExperimental

Subjects assigned to each intervention group will take one capsule daily within 30 minutes before breakfast throughout the 12-week intervention period.

Dietary Supplement: LR1349_high dose